Synonyms: cholest-5-en-3β-ol
Compound class:
Metabolite
|
|
Natural/Endogenous Targets | ||
|
Selectivity at nuclear hormone receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
Targets where the ligand is described in the comment field | |
Target | Comment |
CYP11A1 | Converts cholesterol to pregnenolone plus 4-methylpentanal. |
CYP7A1 | Converts cholesterol to 7α-hydroxycholesterol [4]. |
CYP46A1 | Converts cholesterol to 24(S)-hydroxycholesterol. |
CYP27A1 | Converts cholesterol to 27-hydroxycholesterol. Autosomal-recessive mutations in CYP27A1 cause the bile acid metabolism disorder cerebrotendinous xanthomatosis (CTX, cerebral cholesterosis) [1,3]. An adenovirus vector encoding human CYP27A1 (VTX-806; Vivet Therapeutics) is being trialled as a gene replacement therapy for CTX. VTX-806 was granted Orphan Drug Designation by the EMA in September 2024 for this rare disease. |
Ligand mentioned in the following text fields |
1F. Retinoic acid-related orphans overview |
Bile acid receptor overview |
Class Frizzled GPCRs comments |